Navigation Links


Nimotuzumab in Medical News

YM BIOSCIENCES REPORTS FIRST QUARTER 2008 OPERATIONAL AND FINANCIAL RESULTS

... preliminary results of a Phase I/II trial of nimotuzumab in combination with radiation for the treatment of...ised YM that it had completed enrollment in a nimotuzumab safety trial. There were no limiting toxicities. ...include but are not limited to the following: that nimotuzumab will continue to demonstrate a competitive safety ...
Nimotuzumab in Medical Technology

YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB PRESENTATIONS TO BE MADE AT THE 100TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH AND EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY

MISSISSAUGA, ON, March 13 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Alternext US:YMI, TSX:YM, AIM:YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today reported that its poster entitled, "Binding properties of the ant...

YM BioSciences Announces Milestone Payment For Approval Of Nimotuzumab In The Philippines And Indonesia

MISSISSAUGA, Canada, Dec. 12 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Alternext US:YMI, TSX:YM, AIM:YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced that its majority-owned subsidiary CIMYM BioSciences...

YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain

...terly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that nimotuzumab will continue to demonstrate a competitive safety profile in ongoing and future clinical trials; and that YM and its various partners will complete th...

YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy

...The study also confirms previous observations that nimotuzumab inhibits ligand-dependent EGF receptor downstream ...aling. Daiichi Sankyo Co., Ltd is the licensee for nimotuzumab in Japan. In addition, YM BioSciences announced that a paper on the structure of nimotuzumab entitled 'Modeling the interaction between the ant...

YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial

...terly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that nimotuzumab will continue to demonstrate a competitive safety profile in ongoing and future clinical trials; that AeroLEF(TM) will continue to generate positive e...
Nimotuzumab in Biological Technology

YM BIOSCIENCES ANNOUNCES RESULTS OF RANDOMIZED NIMOTUZUMAB STUDY TO BE PRESENTED IN A POSTER AT ASCO ANNUAL MEETING

MISSISSAUGA, ON, May 28 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: YMI , TSX:YM, AIM:YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced that a poster presentation will report results from a randomiz...

YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER

MISSISSAUGA, ON, Jan. 5 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Alternext US:YMI, TSX:YM, AIM:YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced that it has received clearance from Canadian regulatory a...

YM BIOSCIENCES' NIMOTUZUMAB SELECTED FOR MULTINATIONAL PHASE III TRIAL BY NATIONAL CANCER CENTRE OF SINGAPORE

Singapore investigators to coordinate 700 patient trial of EGFR targeting antibody for treatment of head and neck cancer MISSISSAUGA, ON, Jan. 5 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Alternext US:YMI, TSX:YM, AIM:YMBA), an oncology company that identifies, develops and ...

NOTICE OF YM BIOSCIENCES CONFERENCE CALL TO DISCUSS PHASE II DATA FOR NIMOTUZUMAB IN METASTATIC COLORECTAL CANCER

MISSISSAUGA, ON, Aug. 5 /PRNewswire-FirstCall/ - YM BioSciences Inc. (AMEX: YMI , TSX: YM, AIM: YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, will hold a conference call hosted by Mr. David Allan, Chairman and CEO, at 1...

YM BIOSCIENCES REPORTS NIMOTUZUMAB NSCLC CLINICAL DATA AT ASCO ANNUAL MEETING

MISSISSAUGA, June 2 /PRNewswire-FirstCall/ - YM BioSciences Inc. (AMEX: YMI, TSX: YM, AIM: YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced that updated preliminary trial results, including survival, respons...

YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB COLORECTAL CANCER TRIAL FIRST COHORT IS CLOSED TO ACCRUAL

MISSISSAUGA, ON, Dec. 20 /PRNewswire-FirstCall/ - YM BioSciences Inc. (AMEX: YMI , TSX: YM, AIM: YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced that it has completed accrual in the first 50-patient cohort...

YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION

Data Presented at the 12th World Conference on Lung Cancer in Seoul, Korea MISSISSAUGA, ON, Sept. 4 /PRNewswire-FirstCall/ - YM BioSciences Inc. (AMEX: YMI , TSX: YM, AIM: YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, to...

YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer

MISSISSAUGA, ON, Aug. 30 /PRNewswire-FirstCall/ - YM BioSciences Inc. (AMEX: YMI , TSX: YM, AIM: YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced that its wholly-owned US subsidiary, YM BioSciences USA Inc....

YM BIOSCIENCES', EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER

MISSISSAUGA, ON, Aug. 21 /PRNewswire-FirstCall/ - YM BioSciences Inc. (AMEX: YMI , TSX: YM, AIM: YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced that Oncoscience AG (Wedel, Germany), its European partner f...

YM BIOSCIENCES REPORTS DAIICHI-SANKYO ENROLLS FIRST PATIENTS IN PHASE II, FIRST-LINE LUNG CANCER TRIAL WITH NIMOTUZUMAB

MISSISSAUGA, ON, June 23 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: YMI , TSX:YM, AIM:YMBA), a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, today reported that its li...
Other TagsUltraFit
(Date:12/4/2009)...c. 4 The following is a... Family Philanthropies: ,, Credit Senators John...ficant contribution to the health care debate: a b...living with Phenylketonuria (PKU) control their po...living with serious chronic conditions are treated...
(Date:12/4/2009)...lly conveys true personality, study finds , ... profile on an online social network, such as Face...it does, reports a new study, which finds that peo...dealized identities. , "I was surprised by the...at people are using their profiles to promote an e...
(Date:12/4/2009)...elecoms technology company GemaTech launches its n...rtable Recovery Unit (PRU) is a call re-routing so... The PRU enables organisations to rapidly re-route... phones in any location, with additional voice rec...following a disruption . , ...
(Date:12/4/2009)..., Dec. 4 MedClean Techno...unced the Company has entered into a preferred sto...LC, a Delaware limited liability company, doing b.... Pursuant to the Purchase Agreement, MedClean wil...e Company agreed to sell up to 750 shares of its S...
(Date:12/4/2009)... Dec. 4 PD-Rx Pharmaceut...venue of $5,012,334 for the first quarter ended Se...iod last year. Operating income and net income fo...ely, each a 70% decrease over the same period last...n pharmacy sector sales. This trend is expected t...
Breaking Medicine News(10 mins):Health News:Health Leadership from Sen. Kerry and Sen. Casey: A Cure for Devastating Discrimination in Insurance Coverage for PKU Patients is on the Move 2Health News:Health Leadership from Sen. Kerry and Sen. Casey: A Cure for Devastating Discrimination in Insurance Coverage for PKU Patients is on the Move 3Health News:Online Identities Likely to Match Reality 2Health News:GemaTech Launches Portable Recovery Unit. The Latest Design in Emergency Telecoms Resilience and Continuity 2Health News:MedClean Technologies Enters Into Preferred Stock Agreement of Up to $7.5 Million 2Health News:MedClean Technologies Enters Into Preferred Stock Agreement of Up to $7.5 Million 3Health News:PD-Rx Pharmaceuticals, Inc. Reports 1st Quarter Earnings 2
(Date:12/3/2009)...on windows or solar panels that repels grime and d...ext electric car? New Tel Aviv University research...ls a breakthrough in assembling peptides at the na...sions come true in just a few years. , Operating...onth of a meter) and even smaller, graduate studen...
(Date:12/3/2009)..., Mich. (Dec. 3, 2009) Van Andel Research Insti...how the plant hormone abscisic acid (ABA) works at...ironmental stresses such as drought and cold. The...uld help engineer crops that thrive in harsh envir...ortages. The findings could also have implication...
(Date:12/3/2009)...searchers have measured CO2 levels for the past th...er a sparsely inhabited rural area near Valladolid...n the Iberian Peninsula, show that the levels rose...ecent years, physicists and meteorologists have be...evels, and how these have evolved in the troposphe...
Breaking Biology News(10 mins):A window that washes itself? 2VAI researchers find long awaited key to creating drought resistant crops 2VAI researchers find long awaited key to creating drought resistant crops 3CO2 levels rising in troposphere over rural areas 2New Website for Disability Insurance Launched by Set for Life Insurance by KF Financial 58839 1New Website for Disability Insurance Launched by Set for Life Insurance by KF Financial 58839 2National report shines light on lupus 50 year treatment drought 10254 1National report shines light on lupus 50 year treatment drought 10254 2National report shines light on lupus 50 year treatment drought 10254 3Acne Scars Significantly Improved by a Combination Treatment of Photodynamic Therapy and Percutaneous Collagen Induction 5202 1Acne Scars Significantly Improved by a Combination Treatment of Photodynamic Therapy and Percutaneous Collagen Induction 5202 2
Other Contentstracheidstracheophytestranscripttranscripttranscripttranscriptfacefacefacefacefacefacefacefacefacetranscriptasetranscriptasetranscriptasetranscriptasetranscriptasetranscriptasefactorfactorfactorfactorfactorfactorfactorfactorfactorfactorstartstartstartstartstartstartstartstartstart